San Francisco's Zephyr Health is attracting lots of attention thanks to its software for ranking doctors' influence on others, a valuable metric when deciding whom the sales team should visit, or whom to invite to a conference. And it has branched into the device world. Along with Big Pharma players Amgen ($AMGN) and GlaxoSmithKline ($GSK), the company counts Stryker ($SYK) as one of its customers. "You're desperate for data to make those key (sales and marketing) decisions," Zephyr CEO Lance Scott told Bloomberg. "But while there's lots of data out there, it's really challenging to bring it together." The company has about $34 million in VC funding. Backers include GV (formerly Google Ventures), which boasts a life science portfolio worth $800 million. More